Exploring the Benefit of Peripheral Nerve Stimulation in Treating Pain From Chemo-induced Peripheral Neuropathy: A Longitudinal Single Center Feasibility Study

NCT06162403

Status	RECRUITING
Phase	Not Applicable
Sponsor	M.D. Anderson Cancer Center
Enrollment	10 participants

Key Eligibility Criteria

Inclusion (4)

- Participants diagnosed with chronic (e90 days duration) CIPN (due to either vinca alkaloids, taxanes, bortezomib, thalidomide, platinum-based compounds or ionizing irradiation) of the lower extremity, seen at Pain Management Center at MD Anderson Cancer Center
- Participants reports baseline pain e 4 (0-10 scale, NRS)
- Participants between ages 18-85 years old
- Participants who have completed chemotherapy within the previous year at the time of enrollment

Exclusion (5)

- Participants with cognitive dysfunction
- Participants with recent history (\<6 months) of drug or alcohol abuse
- Participants with open skin lesion or undergoing antibiotic therapy for local for systemic infection
- Participants with allergies to local anesthesia, steroids, or adhesives
- Participants with conditions that conflict with the SPRINT PNS System Indications for Use, including Contraindications and Warnings.

Locations (1 total)

MD Anderson Cancer Center, Houston, Texas, United States

DISCLAIMER: This document is for informational purposes only and does not constitute medical advice. Always consult your healthcare provider before enrolling in any clinical trial. Information may not be up to date — verify details at ClinicalTrials.gov. Generated by ClinicalTrialsFinder.org.